• 1
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention – Updated 2007 (available at:; last accessed June 2008).
  • 2
    Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:17201745.
  • 3
    Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30:452456.
  • 4
    O’Byrne P, Pedersen S, Lamm CJ, Tan W, Busse W. Severe exacerbations, decline in lung function and inhaled budesonide in asthma. Eur Respir J 2007;30:619S.
  • 5
    Humbert M, Holgate S, Boulet LP, Bousquet J. Asthma control or severity: that is the question. Allergy 2007;62:95101.
  • 6
    Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O’Byrne P et al. GINA guidelines on asthma and beyond. Allergy 2007;62:102112.
  • 7
    Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802807.
  • 8
    Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:4047.
  • 9
    Haughney J, Barnes G, Partridge M, Cleland J. The Living & Breathing Study: a study of patients’ views of asthma and its treatment. Prim Care Respir J 2004;13:2835.
  • 10
    Partridge MR, Van der MT, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
  • 11
    National Heart LaBI. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007 (available at:
  • 12
    Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836844.
  • 13
    Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123:14801487.
  • 14
    Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New Engl J Med 1997;337:14051411.
  • 15
    Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219224.
  • 16
    Bateman ED, Bantje TA, Joao GM, Toumbis MG, Huber RM, Naya I et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2003;2:275281.
  • 17
    Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367376.
  • 18
    Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 2007;119:344350.
  • 19
    Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003;97:555562.
  • 20
    O’Byrne PM, Naya I, Källén A, Postma D, Barnes PJ. The role of increasing the dose of an inhaled corticosteroid compared to adding a long acting beta2-agonist in achieving asthma control. Am J Respir Crit Care Med 2007;175:A188.
  • 21
    Pedersen SE, Bateman ED, Bousquet J, Busse WW, Yoxall S, Clark TJ. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol 2007;120:10361042.
  • 22
    Reddel HK. Goals of asthma treatment: how high should we go? Eur Respir J 2004;24:715717.
  • 23
    Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007;29:587595.
  • 24
    Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61:518526.
  • 25
    Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 2000;117:440446.
  • 26
    Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70:288298.
  • 27
    Heiner MM. Key barriers to optimal management of adult asthma in Australia: physician and patient perspectives. Curr Med Res Opin 2007;23:17991807.
  • 28
    Canonica GW, Baena-Cagnani CE, Blaiss MS, Dahl R, Kaliner MA, Valovirta EJ. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy 2007;62:668674.
  • 29
    Partridge MR. Asthma: 1987-2007. What have we achieved and what are the persisting challenges? Prim Care Respir J 2007;16:145148.
  • 30
    Roberts NJ, Robinson DS, Partridge MR. How is difficult asthma managed? Eur Respir J 2006;28:968973.
  • 31
    Angus R, Reagon R, Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract 2005;59:156162.
  • 32
    Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006;61:663670.
  • 33
    Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O’Byrne PM et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594599.
  • 34
    Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000;94:607611.
  • 35
    O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129136.
  • 36
    Tattersfield AE, Löfdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001;357:257261.
  • 37
    Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22:787794.
  • 38
    Cheung D, Van Klink HC, Aalbers R. Improved lung function and symptom control with formoterol on demand in asthma. Eur Respir J 2006;27:504510.
  • 39
    Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244249.
  • 40
    Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13:988992.
  • 41
    FitzGerald JM, Gibson PG. Asthma exacerbations - 4: Prevention. Thorax 2006;61:992999.
  • 42
    Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246256.
  • 43
    Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20:14031418.
  • 44
    Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725736.
  • 45
    Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744753.
  • 46
    Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819828.
  • 47
    Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007;101:24372446.
  • 48
    Aalbers R, Backer V, Kava TT, Omenaas ER, Sandstrom T, Jorup C et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004;20:225240.
  • 49
    Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 2007;23:18671878.
  • 50
    Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149:604610.
  • 51
    Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902907.
  • 52
    Juniper EF, Svensson K, Mörk AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553558.
  • 53
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:8187.
  • 54
    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:1526.
  • 55
    Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904912.
  • 56
    Anderson HR, Ayres JG, Sturdy PM, Bland JM, Butland BK, Peckitt C et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005;330:117.
  • 57
    Jaeschke R, Mejza F, Lesniak W, Brozek J, Schunemann HJ, Guyatt G et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Am J Respir Crit Care Med 2007;175:A57.
  • 58
    Sears M, Ottosson A, Radner F, Suissa S. Safety of formoterol in asthma trials. Eur Respir Trials 2007;30:P1586.
  • 59
    Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des 2006;12:32613279.
  • 60
    Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182191.
  • 61
    Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995;268:L41L46.
  • 62
    Mak JC, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest 1995;96:99106.
  • 63
    Mak JC, Hisada T, Salmon M, Barnes PJ, Chung KF. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol 2002;135:987996.
  • 64
    Tintinger GR, Anderson R, Theron AJ, Ramafi G, Ker JA. Comparison of the effects of selective and non-selective beta-adrenoceptor agonists on the pro-inflammatory activities of human neutrophils in vivo. Inflammation 2000;24:239249.
  • 65
    Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 2003;21:989993.
  • 66
    Paredi P, Kharitonov SA, Barnes PJ. Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res 2005;6:15.
  • 67
    Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med 2001;163:3236.
  • 68
    Tsai YG, Lee MY, Yang KD, Chu DM, Yuh YS, Hung CH. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Pediatr 2001;139:433437.
  • 69
    Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:6472.
  • 70
    Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007;119:322327.
  • 71
    Sears MR, Boulet LP, Laviolette M, Fitzgerald JM, Bai T, Kaplan A et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 2008;31:982989.
  • 72
    Baluk P, McDonald DM. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol 1994;266:L461L468.
  • 73
    Chong LK, Peachell PT. Beta-adrenoceptor reserve in human lung: a comparison between airway smooth muscle and mast cells. Eur J Pharmacol 1999;378:115122.
  • 74
    Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002;360:12931299.
  • 75
    Pang L, Knox AJ. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000;23:7985.
  • 76
    Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59:9499.
  • 77
    AstraZeneca. Symbicort Prescribing Information. 2007 (available at:; last accessed November 2007).
  • 78
    Fält A, Bengtsson T, Kennedy BM, Gyllenberg A, Lindberg B, Thorsson L et al. Exposure of infants to budesonide through breast milk of asthmatic mothers. J Allergy Clin Immunol 2007;120:798802.
  • 79
    Barnes PJ. Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ 2007;335:513.
  • 80
    Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007;62:11891198.
  • 81
    Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24:695708.
  • 82
    Bousquet J, Miravitlles M, Wirén A. Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment. Eur Respir J 2007;30:P1185.